SIREN : 800602401
IMPLANTOLAB is a French company founded 12 years ago, specialized in the sector Fabrication de matériel médico-chirurgical et dentaire. Based in BLOIS (41000), this company of category PME shows in 2022 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | 1 578 198 € | 1 453 467 € | N/C | 736 916 € |
| Net income | 261 168 € | 260 995 € | 154 162 € | 63 488 € | 204 439 € | 121 964 € | 68 937 € |
| EBITDA | N/C | N/C | N/C | 138 697 € | 304 182 € | N/C | 145 158 € |
| Net margin | N/C | N/C | N/C | 4.0% | 14.1% | N/C | 9.4% |
In 2025, IMPLANTOLAB generates positive net income of 261 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2025: 69 k€ -> 261 k€.
261 168 €
The debt ratio (= Financial debt / Equity x 100) stands at 17%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 59%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
17.212%
58.977%
37.2%
In 2025, the debt ratio of IMPLANTOLAB (17.21) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of IMPLANTOLAB (59.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
The liquidity ratio (= Current assets / Current liabilities) stands at 257.24. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
257.24
In 2025, the liquidity ratio of IMPLANTOLAB (257.24) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Based on 57 transactions of similar company sales
(all years),
the value of IMPLANTOLAB is estimated at
795 434 €
(range 184 848€ - 1 568 560€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 57 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare IMPLANTOLAB with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de matériel médico-chirurgical et dentaire
The revenue of IMPLANTOLAB in 2022 is 1.6 M€.
Yes, IMPLANTOLAB generated a net profit of 261 k€ in 2025.
The headquarters of IMPLANTOLAB is located in BLOIS (41000), in the department Loir-et-Cher.
The tax return of IMPLANTOLAB is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
IMPLANTOLAB operates in the sector Fabrication de matériel médico-chirurgical et dentaire (NAF code 32.50A). See the 'Sector positioning' section above to compare the company with its competitors.